All podcasts / The Tim Ferriss Show / Summary

Reimagining Biotech with Jake Becraft of Strand Therapeutics - Tim's Founder Kitchen

2026-06-02 - source - Read full transcript
Tim Ferriss (host)Jacob Becraft

Key insights

A platform therapeutic must share real technological infrastructure across drugs, not just a marketing label.
Becraft argues biotech companies have claimed to be 'platforms' for 20 years, mostly to earn a valuation premium, but a true platform (like Moderna's mRNA vaccine base) means 12+ years of shared technology let a new drug be built in weeks instead of starting over at square one. Strand frames its tumor-delivery and T-cell-delivery systems as separate platforms rather than one universal platform, explicitly to avoid Moderna's overclaiming mistake.
rna-medicine-platforms
Biotech's core unsolved problem isn't 'delivery' in the abstract - it's three separate problems (potency, specificity, delivery) wearing a trenchcoat.
Becraft says the industry's stock answer ('it's a delivery problem') is technically true but useless because it hides three distinct, individually hard subproblems. Strand's founding bet was to solve the second one - getting genetic medicine payloads to organs beyond the liver - which has stalled the field for 30 years.
rna-medicine-platforms
Strand's melanoma trial showed a broad abscopal response in visceral organ metastases, which the field had only ever seen in adjacent, localized tumors before.
By injecting a genetic medicine directly into one tumor, Strand triggered the immune system to also attack untouched tumors deep in the lungs and other organs - not just nearby skin lesions, which is what kills melanoma patients. Two of the first three trial patients (from summer 2024) were still responding 18 months later, an unusually durable phase-1 result.
rna-medicine-platforms
A good drug and a good product are different things, and only the second one scales to patients.
Becraft contrasts CAR-T-style in vivo cell therapy (a great drug that costs $750,000 and three months to manufacture per patient, making it a bad product) with a hypothetical outpatient two-hour IV version (a good product). He argues founders must design for existing care infrastructure - like cancer infusion clinics - not just for biological efficacy, if they want population-level impact.
rna-medicine-platforms
The US is losing the race for first-in-human clinical trials to China because its regulatory process is a $25 million, 18-month tax before a trial even starts.
Becraft describes writing a 22,000-page IND application costing tens of millions of dollars, which pushes companies toward a small number of overburdened top hospitals (MD Anderson, Sloan Kettering) and away from broader access. China has industrialized faster, cheaper trial infrastructure, creating a flywheel where Chinese-discovered drugs increasingly get brought to the US instead of the reverse.
fda-regulatory-reform
Becraft's proposed fix is to move first-in-human trial oversight from the FDA's upfront IND approval to hospital IRBs, modeled on Australia's Clinical Trial Notification (CTN) system.
Under the CTN model, companies notify regulators and go straight to a hospital's Investigational Review Board, which is already incentivized to protect patient safety and already makes the final call on whether to run a trial. This would free the FDA to focus on efficacy/safety approval rather than upfront paperwork, and let more hospitals - not just elite ones - run early trials.
fda-regulatory-reform
Reframing a policy pitch from 'this is broken' to 'this is broken, and here is the fix' is what got traction with Congress and the White House in under two months.
Becraft's Washington Post op-ed led to a congressional hearing invitation within a day, testimony on the Hill about 1.5 weeks later, and language echoing his proposal appeared in the President's legislative priorities roughly two months after the first brainstorming call with Ferriss. Leading with urgency plus a visible solution, rather than just cataloguing problems, was the specific change that unlocked engagement.
founder-storytelling
No one learns until they care - so the founder's first job in any pitch is to make the audience care, not to explain.
Becraft contrasts scientists (who care about any interesting science by default) with investors, policymakers, and the public, who need a reason before they'll absorb technical detail. He applies this by opening with story or a striking image (the melanoma scan) before layering in mechanism.
founder-storytelling
Split-testing headlines and messaging (via PickFu) shaped how Becraft talked about the op-ed in person, even though the published headline itself couldn't be changed.
Tim's team tested several headline/messaging variants with PickFu before Becraft's DC trip; one option won by a wide statistical margin. The value wasn't editing the already-published Washington Post piece but having a data-backed framing to use in testimony, meetings, and shares of the link.
founder-storytelling
Biotech's capital markets are structurally built for incremental exits, not generational company-building, which limits how ambitious founders can be.
Becraft says 90%+ of biotech companies are built to go from 'promising idea' to 'proof it might work' and then sell the asset, more like real-estate development than tech venture-building. The wider effect is a practice called 'short the launch' - public investors bet against biotechs that try to commercialize their own drugs, because so few companies still have that muscle.
capital-formation
The best window to back a company is 'post-conviction, pre-consensus' - after insiders know it works, before the market has caught on.
Becraft applies this framing (citing investors like Thrive Capital's Josh Kushner) to where he believes Strand and platform therapeutics broadly now sit: the internal team already believes the technology works, but broad market consensus (the '$500B-plus market cap moment,' as with OpenAI post-ChatGPT) hasn't arrived yet.
capital-formation
Losing the global race on first-in-human trial speed is existential for US biotech leadership, not just an efficiency problem.
Becraft argues capital 'has no allegiance' - if China keeps running faster, cheaper trials, investment and discovery will keep migrating there, and the US will end up paying for medicines developed elsewhere. He rates the odds of meaningful US regulatory reform within two years at roughly 50%, and flags the UAE as another country aggressively courting biotech investment and talent.
us-china-biotech-competition

Books referenced

Media referenced

Companies

Techniques and frameworks

Summary

Jake Becraft, CEO and co-founder of Strand Therapeutics, joins Tim Ferriss for a two-part "Founder Kitchen" conversation recorded roughly two months apart. The first half is a straightforward founder interview: what Strand does (programmable RNA medicines that trick cancer cells into signaling the immune system to attack them), the striking clinical result behind it (a stage 4 melanoma patient whose visceral organ metastases cleared and stayed clear 18 months later), and Becraft's argument that biotech's real bottleneck isn't "delivery" as a vague catch-all but three distinct hard problems - potency, specificity, and delivery - that the field conflates. He walks through the SpaceX analogy that recurs throughout the episode: build a reusable, first-principles engineering platform before chasing the hardest end use case, the same way Falcon 1 preceded Starship.

From there the conversation turns to policy. Becraft describes the US's first-in-human clinical trial system as increasingly uncompetitive: a $25 million, 22,000-page IND application before a trial can even start, versus Australia's and China's faster IRB-driven or CTN-based systems. He proposes shifting oversight from FDA pre-approval to certified hospital IRBs, arguing this would both speed trials and distribute them beyond a handful of elite hospitals. He frames this as existential for US biomedical leadership: capital is already flowing toward China's faster, cheaper trial infrastructure, and countries like the UAE are aggressively courting biotech investment.

The second half of the episode picks up two months later and is explicitly about what happened after the two of them worked on Becraft's messaging together: a Washington Post op-ed that went viral in policy circles, a congressional hearing invitation within a day, testimony on the Hill, and language echoing his proposal showing up in the President's legislative priorities. Much of this section is a meta-conversation about persuasion itself - how Ferriss's team used PickFu to split-test headlines and messaging, how leading with "problem plus solution" rather than just cataloguing what's broken made policymakers actually engage, and Becraft's repeated point that "no one learns until they care," so the founder's first job in any pitch is to earn attention before delivering information.

The back half also develops Becraft's broader thesis on platform therapeutics: a real platform means shared technological infrastructure that de-risks every subsequent drug, the way Moderna's 12 years of mRNA vaccine R&D let it build a COVID vaccine in 62 days - contrasted with the common, often false biotech claim of being a "platform company." He uses Apple's iPhone (a delivery platform other companies build on) and Amazon's AWS (a hidden platform in the middle of the business) as the closer analogies for what he wants Strand's tumor-delivery and eventual T-cell, kidney, and brain-delivery platforms to become. He closes on capital formation: biotech's venture ecosystem is structurally built for incremental exits rather than generational company-building, and he cites Bezos's shareholder letters and the "post-conviction, pre-consensus" investing window (echoing Thrive Capital's approach) as models for how he wants Strand to communicate its long-term vision to patient capital.

Throughout, the conversation returns to real historical parallels - Genentech's raw, contract-level founding story, Genzyme's "Placentamobile" era of literal founder-mode biotech, and the little-known fact that Genentech CEO Art Levinson also chaired Apple's board - as evidence that today's biotech industry has drifted from that entrepreneurial, big-swing culture into an M&A-feeder model ("short the launch") serving big pharma's acquisition pipeline.

Notable Quotes

"It's three children in their father's trench coat pretending to be an adult... potency, specificity, and delivery are all here inside." - Jacob Becraft

"No one will learn until they care. So your first goal is to make someone care about what you're doing, then they'll learn." - Jacob Becraft

"We're post-conviction. We're no longer saying, 'Can we do this?' We're like, 'Oh my God, this is going to work.' But it's pre-consensus because not everyone has caught on yet." - Jacob Becraft

"I don't want to build a better mousetrap to catch more mice for this one person and exit out of the company. We want to fundamentally change how we're able to build medicines." - Jacob Becraft

"If you come to them and you say, 'Everything's bad and it's burning and we're done,' I mean, honestly, what is anyone going to do?" - Jacob Becraft